AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11115050 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 48 weeks in non-responders
Number of subjects: 120
Study 11115050 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b plus ribavirin for 24 weeks in non-responders
Number of subjects: 120
Study 11115050 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ALT level and undetectable HCV RNA at week 12
Number of subjects: 120
Study 11115050 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA positive at week 12
Number of subjects: 120
Study 9058441 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet providing 20 g/d lactose
Number of subjects: 14
Study 9058441 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free diet
Number of subjects: 14
Study 8375836 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment program (18 weeks)
Number of subjects: 0
Study 8375836 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed-treatment)
Number of subjects: 0
Study 3890505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil (16 mg)
Number of subjects: 22
Study 3890505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (10 mg)
Number of subjects: 22
Study 3890505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (verapamil and metoprolol)
Number of subjects: 22
Study 3890505 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg) during upright bicycle exercise
Number of subjects: 22
Study 3890505 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (16 mg) during upright bicycle exercise
Number of subjects: 22
Study 3890505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy during upright bicycle exercise
Number of subjects: 22
Study 30797084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin 1500 mg intravenously as a single dose
Number of subjects: 698
Study 30797084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin 1000 mg followed by 500 mg a week later (two doses)
Number of subjects: 698
Study 30797084 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 698
Study 30797084 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 698
Study 29475792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing removed on postoperative day 1 (group A, n=40)
Number of subjects: 80
Study 29475792 — intervention group
Group type: COMPARATOR
Intervention: Dressing removed on postoperative day 6 (group B, n=40)
Number of subjects: 80
Study 27632267 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading with two Straumann implants splinted with a Dolder bar, loaded within 48 hours postoperative.
Number of subjects: 40
Study 27632267 — intervention group
Group type: COMPARATOR
Intervention: Early loading with two Straumann implants, loaded 6 weeks postoperative.
Number of subjects: 40
Study 1425713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg/12 h)
Number of subjects: 70
Study 1425713 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg/12 h)
Number of subjects: 70
Study 22880973 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined psychosocial intervention with emergency feeding program
Number of subjects: 147
Study 22880973 — intervention group
Group type: COMPARATOR
Intervention: Nutritional support alone (contrast group)
Number of subjects: 147
Study 20416067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroidism (HYPER)
Number of subjects: 56
Study 20416067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism (HYPO)
Number of subjects: 56
Study 20416067 — intervention group
Group type: COMPARATOR
Intervention: Subclinical hypothyroidism (SCH)
Number of subjects: 56
Study 20416067 — intervention group
Group type: COMPARATOR
Intervention: Normal (N)
Number of subjects: 56
Study 18689384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose potassium citrate (55.5 mEq/d)
Number of subjects: 276
Study 18689384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose potassium citrate (18.5 mEq/d)
Number of subjects: 276
Study 18689384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 18689384 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g additional fruit and vegetables/d (equivalent of 18.5 mEq alkali)
Number of subjects: 276
Study 15932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 100 IR grass pollen extract
Number of subjects: 71
Study 15932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 300 IR grass pollen extract
Number of subjects: 71
Study 14674834 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering the vomeronasal duct (VND)
Number of subjects: 0
Study 14674834 — intervention group
Group type: COMPARATOR
Intervention: Not covering the vomeronasal duct (VND)
Number of subjects: 0
Study 14674834 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection thresholds of androstenone
Number of subjects: 0
Study 10350223 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast, a cysteinyl leukotriene receptor antagonist, administered for 14 days
Number of subjects: 0
Study 10350223 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0
Study 8607661 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg bolus over 2 minutes followed by a 30-minute infusion of 0.375 mg/min and then 0.125 mg/min for 3 days)
Number of subjects: 199
Study 8607661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 8607661 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 199
Study 1836595 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily plasma exchanges with fresh frozen plasma (15 ml/kg) in albumin (45 ml/kg)
Number of subjects: 40
Study 1836595 — intervention group
Group type: COMPARATOR
Intervention: Daily transfusions of fresh frozen plasma (15 ml/kg)
Number of subjects: 40
Study 6429905 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly supervision of CBD family planning programs
Number of subjects: 0
Study 6429905 — intervention group
Group type: COMPARATOR
Intervention: Monthly supervision of CBD family planning programs
Number of subjects: 0
Study 31743175 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub applied on gloves every 15 minutes (total of 8 applications)
Number of subjects: 50
Study 31743175 — intervention group
Group type: COMPARATOR
Intervention: New, unused gloves (control group)
Number of subjects: 50
Study 31743175 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub on gloves
Number of subjects: 50
Study 30270019 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 0
Study 30270019 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 30270019 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training + High-Intensity Interval Training (ST + HIIT)
Number of subjects: 0
Study 27465148 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related medical rehabilitation program
Number of subjects: 504
Study 27465148 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical rehabilitation program
Number of subjects: 504
Study 24613436 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (1 × 10(9) CFU, Lactobacillus rhamnosus GG and Bifidobacterium infantis per day for 28 days)
Number of subjects: 184
Study 24613436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 22071024 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist osteoporosis screening intervention (education, pamphlets, point‐of‐care quantitative heel ultrasound [QUS])
Number of subjects: 262
Study 22071024 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 262
Study 22071024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (education, pamphlets, QUS)
Number of subjects: 262
Study 22071024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients only
Number of subjects: 262
Study 19875651 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (shorter acclimatization time)
Number of subjects: 25
Study 19875651 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (longer acclimatization time)
Number of subjects: 25
Study 19875651 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 25
Study 17665339 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone cage
Number of subjects: 37
Study 17665339 — intervention group
Group type: COMPARATOR
Intervention: Cage + anterior plate fixation
Number of subjects: 37
Study 17382734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% glycine
Number of subjects: 250
Study 17382734 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 250
Study 17382734 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine assay
Number of subjects: 250
Study 15624267 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/day plus MPA 1.25 mg/day (Group B)
Number of subjects: 112
Study 15624267 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day plus MPA 2.5 mg/day (Group A)
Number of subjects: 112
Study 15624267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 11268466 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen only for 4 years
Number of subjects: 250
Study 11268466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus 6 cycles of standard CMF
Number of subjects: 250
Study 11268466 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 250
Study 9180334 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated screws
Number of subjects: 19
Study 9180334 — intervention group
Group type: COMPARATOR
Intervention: Standard screws
Number of subjects: 19
Study 1490039 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 90
Study 1490039 — intervention group
Group type: COMPARATOR
Intervention: Discography
Number of subjects: 90
Study 2951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium 0.5 mg/fenoterol 1.25 mg
Number of subjects: 11
Study 2951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium 0.5 mg/fenoterol 2.5 mg
Number of subjects: 11
Study 2951827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium 0.5 mg/fenoterol 5.0 mg
Number of subjects: 11
Study 2951827 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 5.0 mg
Number of subjects: 11
Study 31707825 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label claim + pro forma disclaimers
Number of subjects: 686
Study 31707825 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label claim + evidence context
Number of subjects: 686
Study 31707825 — intervention group
Group type: COMPARATOR
Intervention: On-label indication
Number of subjects: 686
Study 31707825 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label information from the manufacturer
Number of subjects: 686
Study 27023345 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal exercise programme (weekly classes from the 20th week of pregnancy)
Number of subjects: 51
Study 27023345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise programme)
Number of subjects: 51
Study 26166655 — intervention group
Group type: EXPERIMENTAL
Intervention: mNGF (mouse nerve growth factor) plus systematic rehabilitation training and GM‐1 intervention
Number of subjects: 62
Study 26166655 — intervention group
Group type: COMPARATOR
Intervention: Systematic rehabilitation training and GM‐1 intervention
Number of subjects: 62
Study 23062413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low preoperative urine hepcidin concentration (median, 15.3 ng/mL)
Number of subjects: 100
Study 23062413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low preoperative plasma hepcidin concentration (median, 49.2 ng/mL)
Number of subjects: 100
Study 23062413 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum creatinine
Number of subjects: 100
Study 23062413 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative urine hepcidin
Number of subjects: 100
Study 23062413 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plasma hepcidin
Number of subjects: 100
Study 21895700 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus + gutta‐percha
Number of subjects: 30
Study 21895700 — intervention group
Group type: EXPERIMENTAL
Intervention: I Root SP + gutta‐percha
Number of subjects: 30
Study 21895700 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex + gutta‐percha
Number of subjects: 30
Study 19059553 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Healthy Women intervention
Number of subjects: 692
Study 17133475 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 673
Study 17133475 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LVD)
Number of subjects: 673
Study 14768770 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (1, 2, 3, 4 or 6 mg once daily, n = 111)
Number of subjects: 219
Study 14768770 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (50, 100, 150 or 200 mg 3 times daily, n = 108)
Number of subjects: 219
Study 10720032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adrenomedullin (5.8 pmol/kg x min)
Number of subjects: 8
Study 10720032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adrenomedullin (2.9 pmol/kg x min)
Number of subjects: 8
Study 10720032 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 8
Study 9022839 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training program (upper and lower body exercises, twice per week for 20 weeks)
Number of subjects: 30
Study 9022839 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training program
Number of subjects: 30
Study 9022839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 1286596 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIFN alpha‐1
Number of subjects: 100
Study 1286596 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 100
Study 1286596 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIFN alpha‐1 (cumulative cases)
Number of subjects: 100
Study 4079669 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified amino acid solution enriched in branched-chain amino acids (BAA)
Number of subjects: 70
Study 4079669 — intervention group
Group type: COMPARATOR
Intervention: Conventional amino acid solution (Azonutril)
Number of subjects: 70
Study 30783215 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAZ
Number of subjects: 2012
Study 30783215 — intervention group
Group type: COMPARATOR
Intervention: SPCQ
Number of subjects: 2012
Study 30783215 — intervention group
Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 2012
Study 30419894 — intervention group
Group type: EXPERIMENTAL
Intervention: Community residential aftercare (CRA)
Number of subjects: 41
Study 26774152 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy combined with intraperitoneal hyperthermic chemoperfusion
Number of subjects: 48
Study 26774152 — intervention group
Group type: COMPARATOR
Intervention: Control group (only systemic chemotherapy)
Number of subjects: 48
Study 24400998 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) - 559.2 mg total catechins, 120.4 mg caffeine
Number of subjects: 0
Study 24400998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22997793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrastructural acupotomy therapy at the counter‐Ashi points, treatment given once a week for 1 month.
Number of subjects: 60
Study 22997793 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture‐moxibustion therapy, treatment given once daily for 1 month.
Number of subjects: 60
Study 20952270 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal ligature of ITA branches (group 2)
Number of subjects: 126
Study 20952270 — intervention group
Group type: COMPARATOR
Intervention: Truncal ligature of ITA (group 1)
Number of subjects: 126
Study 17954353 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal effort grip strength
Number of subjects: 32
Study 17954353 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal effort grip strength
Number of subjects: 32
Study 17954353 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of maximal isotonic grip effort for velocity
Number of subjects: 32
Study 17954353 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for sensitivity and specificity
Number of subjects: 32
Study 17954353 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall test performance
Number of subjects: 32
Study 15363881 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral self-help treatment
Number of subjects: 56
Study 15363881 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 56
Study 15363881 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after treatment termination
Number of subjects: 56
Study 11288822 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/day)
Number of subjects: 4406
Study 11288822 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine
Number of subjects: 4406
Study 11288822 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone or in combination
Number of subjects: 4406
Study 11288822 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with nitrendipine
Number of subjects: 4406
Study 9625908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (loading dose of 3.2 mg/kg, followed by 1.6 mg/kg daily for 4 days)
Number of subjects: 33
Study 9625908 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine (loading dose of 20 mg/kg, followed by 10 mg/kg every 8 h for at least 48 h, then oral quinine for a total of 7 days)
Number of subjects: 33
Study 7955999 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone (Group 1)
Number of subjects: 204
Study 7955999 — intervention group
Group type: COMPARATOR
Intervention: Diet and oral hypoglycaemic agents (Group 2)
Number of subjects: 204
Study 3677462 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 1254
Study 3677462 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 1254
Study 28854126 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided error-based learning (n = 37)
Number of subjects: 75
Study 28854126 — intervention group
Group type: COMPARATOR
Intervention: Correct motion instruction (n = 38)
Number of subjects: 75
Study 26706833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane therapy
Number of subjects: 2446
Study 26706833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane + Metformin
Number of subjects: 2446
Study 26706833 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment (Tamoxifen followed by Exemestane)
Number of subjects: 2446
Study 24477478 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-nominated target problems (PTPs)
Number of subjects: 48
Study 22542876 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation intensity 0.2 and 0.5mAmp (Group 1)
Number of subjects: 124
Study 22542876 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation intensity between 0.6 and 1mAmp (Group 2)
Number of subjects: 124
Study 22542876 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation intensity equal or higher than 1.1mAmp (Group 3)
Number of subjects: 124
Study 22542876 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter introduced between 3-5cm without looking for a motor response (Group 4)
Number of subjects: 124
Study 19855955 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma PAI-1 levels
Number of subjects: 94
Study 17339122 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration
Number of subjects: 102
Study 17339122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 16336883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% cream on both sides of the face
Number of subjects: 24
Study 16336883 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 4% cream on one side of the face
Number of subjects: 24
Study 16336883 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream on both sides of the face
Number of subjects: 24
Study 11884251 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial velocity gradient (MVG) M‐mode Doppler tissue imaging in the noninvasive study group
Number of subjects: 85
Study 11884251 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial velocity gradient (MVG) M‐mode Doppler tissue imaging in the invasive study group
Number of subjects: 85
Study 11884251 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial velocity gradient (MVG) M‐mode Doppler tissue imaging in the hemodialysis group
Number of subjects: 85
Study 10235548 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Standard
Number of subjects: 50
Study 10235548 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Fast
Number of subjects: 50
Study 10235548 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTPAC
Number of subjects: 50
Study 10235548 — intervention group
Group type: COMPARATOR
Intervention: Full Threshold
Number of subjects: 50
Study 10235548 — intervention group
Group type: EXPERIMENTAL
Intervention: SITA Fast and SITA Standard
Number of subjects: 50
Study 8732374 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase at home followed by placebo in the hospital (A/P group)
Number of subjects: 100
Study 8732374 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by anistreplase (P/A group)
Number of subjects: 100
Study 1887750 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (0.5 mg.kg-1 per dose, two doses)
Number of subjects: 58
Study 1887750 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (0.5 mg.kg-1 per dose, one dose)
Number of subjects: 58
Study 1887750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 58